NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
Brief: Mural Oncology Announces Second Quarter Financial Results And Provides Business Update
Brief: Mural Oncology Announces Plans To Explore Strategic Alternatives
Europe Research Roundup: ArcelorMittal, Ferrari Group, Sodexo
U.S. STOCKS ON THE MOVE-Affirm, Trump Media, Comstock
U.S. STOCKS ON THE MOVE-CrowdStrike, Scholar Rock, Cloudflare
Brief: Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab)
Mural Oncology slumps after halting ovarian cancer drug trials
Brief: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin
Brief: Mural Oncology Announces Q3 2024 Financial Results And Provides Update On Pipeline Progress